Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
The overall incidence of depression and/or anxiety was lower in GLP1-RA users than non-users (6.80 versus 9.36 per 1,000 person-years), with an aHR of 0.8 (95% CI: 0.670.95) for users, after controlling for demographic factors, comorbidities and medications (Table 2)
Our team has found that patients on concurrent GLP-1 therapy (semaglutide, tirzepatide) often benefit from twice-weekly lipo c dosage during the first 812 weeks of treatment, when caloric deficit is steepest and hepatic fat mobilisation is most active
doi:10.1007/s10911-021-09497-0
You can eat what you want, you just want less
Heres where Medicare coverage gets complicated: This distinction diabetes drug vs